Table 1.
Characteristics of included patients
| Renal cell carcinoma | Soft tissue sarcoma | Overall | |
|---|---|---|---|
| Patients (n) | 35 | 26 | 61 |
| Gender (n (%)) | |||
| Male | 22 (62.9) | 14 (53.8) | 36 (59.0) |
| Female | 13 (37.1) | 12 (46.2) | 25 (41.0) |
| Age (mean (range)) | 62 (45–77) | 61 (32–91) | 61 (32–91) |
| Weight (mean (CV%)) | 84 (23.1) | 77 (17.5) | 81 (21.6) |
| Performance status (n (%)) | |||
| 0 | 13 (37.1) | 11(42.3) | 24 (39.3) |
| 1 | 16 (45.7) | 14 (53.8) | 30 (49.2) |
| 2 | 6 (17.1) | 1 (3.8) | 7 (11.5) |
| Pazopanib dose (n (%))* | |||
| 200 mg | 3 (8.6) | 1 (3.8) | 4 (6.6) |
| 400 mg | 5 (14.3) | 2 (7.7) | 7 (11.5) |
| 600 mg | 6 (17.1) | 2 (7.7) | 8 (13.1) |
| 800 mg | 21 (60.0) | 21 (80.8) | 42 (68.9) |
| Previous lines of systemic therapy (median (range)) | 1 (1–4) | 1 (0–2) | 1 (0–4) |
| Number of samples (n) | 151 | 76 | 227 |
| Samples per patients (mean (range)) | 4 (1–17) | 3 (1–9) | 4 (1–17) |
| Mean (CV%) Cmin per patient (mg/L) | 26.9 (36.4) | 31.9 (36.3) | 29.0 (37.1) |
| Patients with mean Cmin < 20 mg/L (n (%)) | 6 (17.1) | 4 (15.4) | 10 (16.4) |
C min Pazopanib trough level/minimum concentration, CV% coefficient of variation
*Lowest dose per patient